Head-To-Head Comparison: Zosano Pharma (ZSAN) and Dyax (DYAX)

Zosano Pharma (NASDAQ: ZSAN) and Dyax (NASDAQ:DYAX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Zosano Pharma and Dyax’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zosano Pharma N/A -169.79% -94.28%
Dyax -47.32% -14.86% -12.09%

Insider and Institutional Ownership

19.7% of Zosano Pharma shares are owned by institutional investors. 3.0% of Zosano Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zosano Pharma and Dyax, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zosano Pharma 0 0 2 0 3.00
Dyax 0 0 0 0 N/A

Zosano Pharma presently has a consensus target price of $3.50, suggesting a potential upside of 503.45%. Given Zosano Pharma’s higher probable upside, equities research analysts clearly believe Zosano Pharma is more favorable than Dyax.

Valuation and Earnings

This table compares Zosano Pharma and Dyax’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zosano Pharma $310,000.00 73.83 -$29.83 million ($1.18) -0.49
Dyax N/A N/A N/A ($0.21) -181.14

Dyax has lower revenue, but higher earnings than Zosano Pharma. Dyax is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Zosano Pharma beats Dyax on 6 of the 9 factors compared between the two stocks.

Zosano Pharma Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Dyax Company Profile

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply